Sector News

Confident Sanofi files pre-merger notification for Medivation

May 13, 2016
Life sciences

Despite reports that Pfizer is now the front-runner to snap up cancer biotech Medivation, its original suitor Sanofi is confident that its low ball $9.3 billion offer will be accepted after filing under the Hart-Scott-Rodino Antitrust Improvements Act.

This move, which happens when a company believes it is about to subsume another company, shows Sanofi’s bullishness in getting the deal done–despite the fact that it was roundly rejected by Medivation just weeks’ ago and comes amid swirling rumors that it has opened talks with Pfizer.

Sanofi has in the past week hinted at both potentially extending its offer–but also going hostile if the Xtandi producer’s board doesn’t play ball.

In a brief statement, the French drugmaker–which is looking to beef up its relatively weak and until recently half abandoned oncology pipeline–said: “As announced on April 28, 2016, Sanofi proposed to acquire Medivation for $52.50 per share, representing an all-cash transaction valued at approximately $9.3 billion”–indicating it is not yet willing to budge on price.

Analysts have said the biotech could fetch as much as $70 a share, with Novartis, AstraZeneca and Amgen also all said to be circling.

By Ben Adams

Source: Fierce Biotech

Join the discussion!

Your email address will not be published. Required fields are marked *

Related News

January 17, 2021

SII expects WHO emergency approval of Covid-19 vaccine soon

Life sciences

The Serum Institute of India (SII) expects to soon receive World Health Organisation (WHO) emergency use authorisation for the Oxford University/AstraZeneca Covid-19 vaccine, produced for mid and low-income countries.

January 17, 2021

Sanofi to acquire clinical-stage biopharma firm Kymab for $1.45bn

Life sciences

According to the deal, Sanofi will gain full global rights to Kymab’s fully human monoclonal antibody, KY1005 that attaches to OX40-Ligand and can potentially treat various immune-mediated diseases and inflammatory ailments.

January 17, 2021

Moderna poaches Amgen vet as CCO, jump-starting commercial team as it rolls out COVID-19 vaccine

Life sciences

Moderna tapped veteran Amgen executive Corinne Le Goff to spearhead that effort as chief commercial officer.

Send this to a friend